– USA, NY – Curemark LLC announced today the closing of $20 million in equity financing from the Frist Family. William and Jennifer Frist are directors in numerous healthcare corporations, foundations and enterprises including Healthcare Corporation of America (HCA). Mrs. Frist joins Curemark’s Board of Directors and will bring her business, patient advocacy and philanthropic experience to Curemark.
“This investment positions the company for growth and expansion,” states Dr. Joan Fallon, Curemark founder and CEO. “We are extremely grateful to Jennifer and Billy for their investment in Curemark and their support of our mission to get CM-AT to children with autism.”
Curemark recently announced the start of a new Phase III double blind, randomized, placebo-controlled clinical trial to examine the effect of its novel formulation, CM-AT, on all children ages 3-8 with Autism. Previously, Curemark announced the successful results of its FDA Phase III double blinded clinical trial for CM-AT in children ages 3-8 with Autism who had low levels of the digestive enzyme chymotrypsin. The Company is currently submitting its rolling New Drug Application for CM-AT for autism under the FDA’s Fast Track designation.
About Curemark LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints.
- Disclaimer - News, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.
Comments are closed.